Abstract Number: 1486 • ACR Convergence 2022
Derivation and Internal Validation of a Disease-specific Cardiovascular Risk Prediction Model for Patients with Psoriatic Arthritis and Psoriasis
Background/Purpose: Cardiovascular risk in patients with psoriatic disease (PsD) may be underestimated by conventional scoring systems. We derived and internally validated a 5-year disease-specific cardiovascular…Abstract Number: 2012 • ACR Convergence 2022
Predictors of Remission in Rheumatoid Arthritis Patients Treated with Biologics: A Systematic Review and Meta-analysis
Background/Purpose: Biologic disease-modifying antirheumatic drugs (bDMARDs) have emerged as an effective treatment of rheumatoid arthritis (RA), improving patients’ quality of life throughout the disease course.…Abstract Number: 0553 • ACR Convergence 2022
Stair Climbing Difficulty and Risk of Functional Limitation in Knee Osteoarthritis: A Simple Functional Vital Sign?
Background/Purpose: Knee osteoarthritis (OA) is a leading cause of functional limitation in older adults, and difficulty with climbing stairs is often the first-reported limitation. As…Abstract Number: 1131 • ACR Convergence 2022
Integrating Genome and Transcriptome-Wide Associations with Real-World Data to Assess Risk for Leukopenia in Patients Taking Azathioprine
Background/Purpose: Azathioprine is used to treat several autoimmune conditions, but its use is limited by side effects. Leukopenia, a severe, potentially life-threatening side effect is…Abstract Number: 1506 • ACR Convergence 2022
Multimorbidity in Psoriasis as a Risk Factor for Psoriatic Arthritis: A Population-Based Study
Background/Purpose: Psoriasis is a systemic inflammatory disorder associated with cardiometabolic and other comorbidities. Psoriasis frequently precedes development of psoriatic arthritis (PsA), and comorbidities in psoriasis…Abstract Number: 2014 • ACR Convergence 2022
Difficult to Treat Rheumatoid Arthritis: Prevalence of Different Objective Patterns, Predictive Characteristics, and Associated Factors in 1-Year Follow-Up
Background/Purpose: Difficult-to-Treat Rheumatoid Arthritis (RA) (D2T), is a concept recently defined by EULAR, it refers to patients who do not achieve the therapeutic target, who…Abstract Number: 0617 • ACR Convergence 2022
Killer Cell Immunoglobulin Receptor and Class I HLA Genetic Variability in South-eastern Spanish Rheumatoid Arthritis Patients
Background/Purpose: Rheumatoid arthritis (RA) is a common chronic inflammatory disorder characterized by bone erosions and progressive joint destruction. Genetic, epigenetic and environmental factors may induce…Abstract Number: 1149 • ACR Convergence 2022
A Novel Mitochondrial Variant as a Predictor for the Rapid Progressive Knee Osteoarthritis Phenotype: Development of a Predictive Model and Functional Studies
Background/Purpose: Knee osteoarthritis progression is heterogeneous in the population, being the most aggresive form the rapid progressive knee osteoarthritis (RPKOA). These patients suffer a worsening…Abstract Number: 1526 • ACR Convergence 2022
Developing a Screening Tool for the Detection of Interstitial Lung Disease in Systemic Sclerosis: The ILD-RISC Risk Score
Background/Purpose: High resolution computed tomography (HRCT) is the gold standard for the diagnosis of systemic sclerosis associated interstitial lung disease (SSc-ILD). Although there is agreement…Abstract Number: 2015 • ACR Convergence 2022
JAK Selectivity Did Not Affect to the Incidence of Malignancies in the Real-World Setting: Data from a Multicenter Observational Study in Japan
Background/Purpose: Tofacitinib and baricitinib are the first and second approved JAK inhibitors for rheumatoid arthritis (RA) patients. Although their clinical efficacy has been well established,…Abstract Number: 0635 • ACR Convergence 2022
Blood RNA-sequencing Reveals Complex Immune Dysregulation in ANA-positive Individuals with Distinct Profiles Preceding Progression to SLE versus Stable Autoimmunity
Background/Purpose: Anti-nuclear antibody (ANA) positivity represents a complex ‘At-Risk’ state for development of connective tissue disease (CTD). ANA may become positive years in advance of…Abstract Number: 1197 • ACR Convergence 2022
Folic Acid and Methotrexate Use and Their Association with COVID-19 Diagnosis and Mortality: An Analysis from the UK Biobank
Background/Purpose: Folate metabolism is implicated in SARS-CoV-2 infectivity. The current study seeks to determine if methotrexate (an antifolate) or folic acid prescription were associated with…Abstract Number: 1590 • ACR Convergence 2022
Pain and Treatment Switching Among Patients in the CorEvitasTM Rheumatoid Arthritis Registry
Background/Purpose: For many patients with RA on targeted therapies, the chronic burden of pain leads to therapies being deemed suboptimally effective and may affect treatment…Abstract Number: 2062 • ACR Convergence 2022
Predicting Severe Flares: Real-world Application of a Decision-Tree Model Among the Medicaid-Insured Systemic Lupus Erythematosus (SLE) Population in the US
Background/Purpose: Systemic lupus erythematosus (SLE) is a complex disease with multisystem inflammation resulting in variable clinical manifestations. As a result, predicting the occurrence of an…Abstract Number: 0680 • ACR Convergence 2022
Association of Environmental Risk Factors with Antiphospholipid Antibodies and Thrombosis in 1199 International Patients Referred for Suspected Antiphospholipid Syndrome
Background/Purpose: Whether environmental risk factors induce antiphospholipid antibody (aPL) positivity and increase the risk of arterial thrombosis (AT) and venous thromboembolism (VTE) in aPL-positive patients…
- « Previous Page
- 1
- …
- 11
- 12
- 13
- 14
- 15
- …
- 23
- Next Page »